FUTURE-SUPER: A randomized, subtyping-based umbrella phase II trial for first-line treatment of metastatic triple-negative breast cancer

被引：0
|
作者：
Shao Zhimin
Fan, Lei
Ma Linxiaoxi
Wu, Songyang
Chen, Li
Liu, Xiyu
Zhang, Wenjuan
Hu, Xin
Jiang, Yizhou
Wang, Zhonghua
Li, Huajun
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[2] Fudan Univ, Dept Breast Surg, Shanghai Canc Ctr, Shanghai, Peoples R China
[3] Fudan Univ, Shanghai Med Coll, Dept Oncol, Key Lab Breast Canc Shanghai, Shanghai, Peoples R China
[4] Jiangsu Hengrui Pharmaceut Co Ltd, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3011
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A Phase II Trial of Selinexor (KPT-330) for Metastatic Triple-Negative Breast Cancer
    Shafique, Michael
    IsmailKhan, Roohi
    Extermann, Martine
    Sullivan, Dan
    Goodridge, Dawn
    Boulware, David
    Hogue, Deanna
    Soliman, Hatem
    Khong, Hung
    Han, Hyo S.
    ONCOLOGIST, 2019, 24 (07): : 887 - +
  • [32] A Phase II Trial of Vinflunine As Monotherapy or in Combination with Trastuzumab as First-Line Treatment of Metastatic Breast Cancer
    Yardley, Denise A.
    McCleod, Michael
    Schreiber, Fred
    Murphy, Patrick
    Patton, Jeffrey
    Thompson, Dana S.
    Shastry, Mythili
    Rubin, Mark
    Melnik, Marianne
    Burris, Howard A.
    Hainsworth, John D.
    CANCER INVESTIGATION, 2010, 28 (09) : 925 - 931
  • [33] A phase II trial of capecitabine and vinorelbine as first-line treatment in patients with metastatic breast cancer (BC)
    Palumbo, Raffaella
    Bernardo, Antonio
    Strada, Maria Rosa
    Poggi, Guido
    Delmonte, Angelo
    Teragni, Cristina
    Frascaroli, Mara
    Bernardo, Giovanni
    ANNALS OF ONCOLOGY, 2006, 17 : 75 - 75
  • [34] Vinorelbine, methotrexate and fluorouracil (VMF) as first-line therapy in metastatic breast cancer: a randomized phase II trial
    Elomaa, I
    Joensuu, H
    Blomqvist, C
    ANNALS OF ONCOLOGY, 2003, 14 (05) : 699 - 703
  • [35] Results of a Randomized Phase II Study Demonstrate Benefit of Platinum-Based Regimen in the First-Line Treatment of Triple Negative Breast Cancer (TNBC).
    Fan, Y.
    Xu, B. H.
    Yuan, P.
    Wang, J. Y.
    Ma, F.
    Ding, X. Y.
    Zhang, P.
    Li, Q.
    Cai, R. G.
    CANCER RESEARCH, 2011, 71
  • [36] Gemcitabine as first-line therapy in patients with metastatic breast cancer: A phase II trial
    Blackstein, M
    Vogel, CL
    Ambinder, R
    Cowan, J
    Iglesias, J
    Melemed, A
    ONCOLOGY, 2002, 62 (01) : 2 - 8
  • [37] Docetaxel-cisplatin might be superior to docetaxel-capecitabine in the first-line treatment of metastatic triple-negative breast cancer
    Fan, Y.
    Xu, B. H.
    Yuan, P.
    Ma, F.
    Wang, J. Y.
    Ding, X. Y.
    Zhang, P.
    Li, Q.
    Cai, R. G.
    ANNALS OF ONCOLOGY, 2013, 24 (05) : 1219 - 1225
  • [38] A phase Ill randomized trial of atezolizumab in combination with nab-paclitaxel as first line therapy for patients with metastatic triple-negative breast cancer (mTNBC)
    Emens, L.
    Adams, S.
    Loi, S.
    Schmid, P.
    Schneeweiss, A.
    Rugo, H.
    Chui, S.
    Winer, E.
    CANCER RESEARCH, 2016, 76
  • [39] Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial
    Schmid, Peter
    Abraham, Jacinta
    Chan, Stephen
    Wheatley, Duncan
    Brunt, Adrian Murray
    Nemsadze, Gia
    Baird, Richard D.
    Park, Yeon Hee
    Hall, Peter S.
    Perren, Timothy
    Stein, Robert C.
    Mangel, Laszlo
    Ferrero, Jean-Marc
    Phillips, Melissa
    Conibear, John
    Cortes, Javier
    Foxley, Andrew
    de Bruin, Elza C.
    McEwen, Robert
    Stetson, Daniel
    Dougherty, Brian
    Sarker, Shah-Jalal
    Prendergast, Aaron
    McLaughlin-Callan, Max
    Burgess, Matthew
    Lawrence, Cheryl
    Cartwright, Hayley
    Mousa, Kelly
    Turner, Nicholas C.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (05)
  • [40] Biomarker analysis of the LOTUS trial of first-line ipatasertib (IPAT) plus paclitaxel (PAC) in metastatic triple-negative breast cancer (TNBC)
    Wongchenko, Matthew J.
    Dent, Rebecca
    Kim, Sung-Bae
    Saura, Cristina
    Oliveira, Mafalda
    Baselga, Jose
    Kapp, Amy V.
    Chan, Wai Y.
    Singel, Stina M.
    Maslyar, Daniel J.
    Gendreau, Steven
    CANCER RESEARCH, 2018, 78 (04)
12345